💊 Aurobindo Pharma Q4FY25 Results: ₹903 Cr Profit, 13.5% US Growth — Pharma Ka Daddy or Just a Dividend-Delayed Darling?

CMP: ₹1,194.70 | Up 1.17% | EPS: ₹15.56 | Revenue: ₹8,382 Cr | P/E: 19.2x

📌 At a Glance

Aurobindo Pharma reported Q4FY25 consolidated revenue of ₹8,382 Cr (up 10.6% YoY) with a net profit of ₹903 Cr. US and Europe drove the show, while growth markets took a nap. Margins held firm despite R&D spends of ₹423 Cr. 5 ANDAs were finally approved in Q4. And the company continues to fire on all cylinders globally.

🏢 About the Company

• HQ: Hyderabad, India
• Listed On: NSE (AUROPHARMA), BSE (524804)
• Founded: 1986
• Global Reach: 150+ countries
• Facilities: 30+ USFDA-approved plants
• Segments: Generics, APIs, ARVs, specialty drugs, R&D, biosimilars

Aurobindo is that pharma nerd in class who never speaks — but always tops the board exams (and the USFDA exam).

👨⚕️ Key Management

• K. Nithyananda Reddy – Vice-Chairman & MD

“All-time high sales and EBITDA. Europe closing in on $1B. We’ve built a revenue rocket, now launching it.”

📊 Q4 FY25 Financials